Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 167

recruiting
3 982
countries
28
conditions
2 106

3 667 trials match your criteria

Parkinson's disease

Not recruiting

Study of IPX203 compared to levodopa/carbidopa in patients with advanced Parkinson's disease and motor fluctuations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Levodopa

Non-small cell lung cancer

Not recruiting

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE

Non-small cell lung cancer stage III

Not recruiting

Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib

Alopecia areata

Not recruiting

Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

Investigational
Countries:ItalyItaly
  • Participants:0–17 years

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate

Endocrine ophthalmopathy

Not recruiting

Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AMG 732

Fabry's disease

Not recruiting

Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Agalsidase beta

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate

PIK3CA related overgrowth spectrum

Not recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Duchenne muscular dystrophy

Not recruiting

Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.